Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
about
Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-squamous histology population.Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in SingaporeImpact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphomaClinical and economic burden of emergency department presentations for neutropenia following outpatient chemotherapy for cancer in Victoria, Australia.Chemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient settingCOST OF FEBRILE NEUTROPENIA TREATMENT IN BOSNIA AND HERZEGOVINA.Supportive Care Costs Associated with Second-Line Chemotherapy in Chinese Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study.Cost effectiveness of first-line treatment with doxorubicin/ifosfamide compared to trabectedin monotherapy in the management of advanced soft tissue sarcoma in Italy, Spain, and sweden.Neutropenia management and granulocyte colony-stimulating factor use in patients with solid tumours receiving myelotoxic chemotherapy--findings from clinical practiceGranulocyte colony-stimulating factors as prophylaxis against febrile neutropenia.Enhancement of Aerosol Cisplatin Chemotherapy with Gene Therapy Expressing ABC10 protein in Respiratory System.Cost of Cancer-Related Neutropenia or Fever Hospitalizations, United States, 2012.Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients.Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.Costs associated with febrile neutropenia in the US.Management of febrile neutropenia--a German prospective hospital cost analysis in lymphoproliferative disorders, non-small cell lung cancer, and primary breast cancer.Management of infection and febrile neutropenia in patients with solid cancer.Healthcare utilisation in patients with breast cancer or non-Hodgkin lymphoma who experienced febrile neutropenia in the Netherlands: a retrospective matched control study using the PHARMO database.The cost of the inpatient management of febrile neutropenia in cancer patients--a micro-costing study in the Irish healthcare setting.The impact of chemotherapy-induced side effects on medical care usage and cost in German hospital care--an observational analysis on non-small-cell lung cancer patients.Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.Potential therapeutic and economic value of risk-stratified treatment as initial treatment of multiple myeloma in Europe.
P2860
Q30977332-3D79CA29-8B44-41FB-AF00-32D346AA1745Q34677539-EB163097-5487-4804-BF1B-216A0A203A95Q35730160-01A9FC68-DE53-4161-B026-0175F71555C8Q36102853-8F90E155-865F-48B4-B8A1-DF1ADBC4EC02Q36741541-796B56FE-C573-437C-87F3-AA7CC12179C2Q36853019-889FE478-093A-4A10-B247-A8303F174497Q36942871-54DEDDEB-E3D9-4081-9C29-22FE2F79424DQ37330372-44CFDB51-296A-48C2-A291-F68F5A373528Q37554901-5F92F9B5-75C1-47A8-8245-49ACE8E3E99EQ38256944-EB9FC203-13FF-498C-BA05-5A245029C41EQ38689201-274B12A2-254D-4121-A44E-66C5CC2CE7DBQ38823135-43E62077-280D-47D4-A83D-E3FB9DEEFFD2Q39779938-AE0D4266-3F80-4380-9DAA-C22848C63D5EQ40206253-06E006AE-1EE3-4A30-B3DB-CB63355DADA2Q40280346-64893114-A19A-473D-AFFD-9137D09FB41CQ40324761-A82A093F-BCCE-478A-BB8F-4FE44FF191BDQ40906626-87F7E76B-6E12-4DFD-AFDC-535CED3E7579Q43571500-89D51EF9-73D2-4AB9-A6B0-D0D7A68080F5Q44711105-827EB5B6-C1BE-4CD9-A248-1B5D81847F00Q46039744-05724F27-D58E-45DD-8053-FF24918B1DB4Q47376469-68B068DA-23C5-4CEC-9783-14395A298629Q48537667-71E1C80F-3EA6-4E93-8F2E-F65F4D61D6AE
P2860
Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Retrospective cost analysis of ...... a in cancer patients in Spain.
@en
Retrospective cost analysis of ...... a in cancer patients in Spain.
@nl
type
label
Retrospective cost analysis of ...... a in cancer patients in Spain.
@en
Retrospective cost analysis of ...... a in cancer patients in Spain.
@nl
prefLabel
Retrospective cost analysis of ...... a in cancer patients in Spain.
@en
Retrospective cost analysis of ...... a in cancer patients in Spain.
@nl
P2093
P1476
Retrospective cost analysis of ...... a in cancer patients in Spain.
@en
P2093
Adolfo Frau
Andrés López
ENIA Study Group
Javier Castellanos
Jordi Sánchez
José Antonio Gasquet
José Ignacio Mayordomo
Juan Domingo Alonso
Miquel Layola
Núria Viñolas
P304
P356
10.1185/03007990903209563
P407
P577
2009-10-01T00:00:00Z